Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
16.05M | 12.06M | 5.93M | 1.49M | 1.49M | 3.53M | Gross Profit |
2.50M | 5.49M | 3.26M | 910.14K | 527.79K | 1.07M | EBIT |
-6.64M | -6.00M | -13.63M | -13.36M | -2.87M | -4.91M | EBITDA |
-9.28M | -13.50M | -24.59M | -16.59M | 16.25M | -3.63M | Net Income Common Stockholders |
-1.66M | -14.15M | -28.59M | -19.43M | 19.92M | -8.92M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
3.84M | 2.20M | 3.83M | 4.38M | 4.57M | 256.60K | Total Assets |
17.86M | 11.78M | 24.18M | 37.33M | 42.65M | 13.21M | Total Debt |
307.94K | 6.84M | 6.60M | 4.28M | 2.23M | 2.44M | Net Debt |
-2.43M | 4.64M | 2.78M | -98.09K | -2.32M | 2.23M | Total Liabilities |
1.76M | 12.07M | 10.93M | 6.17M | 3.95M | 4.56M | Stockholders Equity |
14.34M | 3.96M | 13.97M | 27.38M | 32.94M | 8.33M |
Cash Flow | Free Cash Flow | ||||
-2.22M | -3.39M | -4.17M | -8.86M | -3.26M | -2.61M | Operating Cash Flow |
-1.17M | -3.18M | -3.61M | -8.57M | -3.26M | -2.58M | Investing Cash Flow |
-775.89K | 1.48M | -808.30K | -3.51M | -70.33K | -681.25K | Financing Cash Flow |
77.20K | 95.35K | 3.87M | 11.90M | 7.75M | 737.48K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
59 Neutral | $29.20B | 0.14 | -12.92% | 4.06% | 2.18% | -51.74% | |
55 Neutral | C$20.41M | ― | -14.06% | ― | 48.51% | 89.48% | |
55 Neutral | C$12.55M | ― | -65.49% | ― | 5.42% | -55.46% | |
44 Neutral | C$7.85M | ― | -13.04% | ― | -43.46% | 35.70% | |
44 Neutral | C$1.75M | ― | -158.04% | ― | -26.19% | 24.21% |
Hydreight Technologies Inc. has reported significant growth and achievements in 2023, expanding its network to over 650 cities and increasing its nurse workforce to approximately 3,000. The company provided nearly 40,000 patient services, filled thousands of pharmacy orders, and grew its doctor network to over 100 across the U.S. Hydreight also expanded its product offerings and white label solutions, which now include aesthetics and semaglutide, aiming to enhance patient outcomes and broaden service options.
Victory Square Technologies Inc., along with Hydreight Technologies Inc., has launched a $10 million Digital Health Accelerator program aimed at investing in emerging healthcare brands to improve patient care across the United States. This initiative seeks to capitalize on the projected $7.2 trillion opportunity in the US healthcare market by providing essential infrastructure and resources to healthcare companies, facilitating rapid market entry and expansion without the typical complexities and delays.
Victory Square Technologies Inc. reported a significant financial turnaround in Q3 2024, with a net income of $10.66 million and earnings per share of $0.11, highlighting their successful strategy and diversified portfolio. Key achievements included Hydreight Technologies’ record revenue and the successful launch of VSDHOne telemedicine and e-commerce solution.